Head of Clinic/Clinical Professor University Hospital Brussels

Printed as of 12/14/2025

Disclosures

Personal Commercial (14)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---------------------------|--------------------------|--|
| Self | | | |
| AstraZeneca Pharmaceuticals | Speaker's Bureau | Modest (< \$5,000) | General Cardiology Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Speaker's Bureau | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Bristol-Myers Squibb Company | Speaker's Bureau | Modest (< \$5,000) | Arrhythmias and Clinical EP |
| Bristol-Myers Squibb Company | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| Daiichi Sankyo | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Menarini Group | Speaker's Bureau | Modest (< \$5,000) | Prevention |
| Novartis Corporation | Speaker's Bureau | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis Corporation | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer Inc | Speaker's Bureau | Modest (< \$5,000) | Prevention |
| Roche diagnostics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Roche diagnostics | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/16/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attestation Agreement agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/16/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement Agre

Embargo | Signed on 10/16/2021

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/7/2022

ACC and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.